JP4769481B2 - ポリ−γ−グルタミン酸含有免疫補強剤組成物 - Google Patents
ポリ−γ−グルタミン酸含有免疫補強剤組成物 Download PDFInfo
- Publication number
- JP4769481B2 JP4769481B2 JP2005128003A JP2005128003A JP4769481B2 JP 4769481 B2 JP4769481 B2 JP 4769481B2 JP 2005128003 A JP2005128003 A JP 2005128003A JP 2005128003 A JP2005128003 A JP 2005128003A JP 4769481 B2 JP4769481 B2 JP 4769481B2
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cancer
- poly
- glutamic acid
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004220 glutamic acid Substances 0.000 title claims description 60
- 239000000203 mixture Substances 0.000 title claims description 27
- 239000012744 reinforcing agent Substances 0.000 title description 8
- 108091007433 antigens Proteins 0.000 claims description 96
- 102000036639 antigens Human genes 0.000 claims description 95
- 239000000427 antigen Substances 0.000 claims description 78
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 58
- 229960005486 vaccine Drugs 0.000 claims description 38
- 241000894006 Bacteria Species 0.000 claims description 32
- 239000004310 lactic acid Substances 0.000 claims description 29
- 235000014655 lactic acid Nutrition 0.000 claims description 29
- 101710081079 Minor spike protein H Proteins 0.000 claims description 23
- 230000000890 antigenic effect Effects 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 102000011931 Nucleoproteins Human genes 0.000 claims description 11
- 108010061100 Nucleoproteins Proteins 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 11
- 230000002458 infectious effect Effects 0.000 claims description 11
- 241000701931 Canine parvovirus Species 0.000 claims description 10
- 230000016784 immunoglobulin production Effects 0.000 claims description 9
- 208000005577 Gastroenteritis Diseases 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 241000282898 Sus scrofa Species 0.000 claims description 8
- 239000007929 subcutaneous injection Substances 0.000 claims description 7
- 238000010254 subcutaneous injection Methods 0.000 claims description 7
- 241000700721 Hepatitis B virus Species 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 5
- 201000007983 brain glioma Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 201000005102 vulva cancer Diseases 0.000 claims description 5
- 210000002421 cell wall Anatomy 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 108010049048 Cholera Toxin Proteins 0.000 claims description 3
- 102000009016 Cholera Toxin Human genes 0.000 claims description 3
- 101710136297 Protein VP2 Proteins 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 3
- 239000007928 intraperitoneal injection Substances 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 108010015899 Glycopeptides Proteins 0.000 claims description 2
- 102000002068 Glycopeptides Human genes 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 108010067390 Viral Proteins Proteins 0.000 claims description 2
- 229960001212 bacterial vaccine Drugs 0.000 claims description 2
- 229940096529 carboxypolymethylene Drugs 0.000 claims description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000004606 Fillers/Extenders Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- GGHDAUPFEBTORZ-UHFFFAOYSA-N propane-1,1-diamine Chemical compound CCC(N)N GGHDAUPFEBTORZ-UHFFFAOYSA-N 0.000 claims 1
- 229960002989 glutamic acid Drugs 0.000 description 59
- 239000003795 chemical substances by application Substances 0.000 description 35
- 210000000234 capsid Anatomy 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 241000282887 Suidae Species 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 235000010210 aluminium Nutrition 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940021747 therapeutic vaccine Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- -1 For example Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000016379 mucosal immune response Effects 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940126578 oral vaccine Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (z)-octadec-9-enoate Chemical compound OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 description 1
- KGQXGYOTPHIRRK-UHFFFAOYSA-N 3-ethyl-1-benzothiophene-2-sulfonic acid Chemical compound C(C)C1=C(SC2=C1C=CC=C2)S(=O)(=O)O KGQXGYOTPHIRRK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000006456 gs medium Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Description
ポリ−γ−グルタミン酸製造用基本培地(5%のL−グルタミン酸が添加されたGS培地;グルコース:5%、(NH4)2SO4:41%、KH2PO4:0.27%、Na2HPO4・12H2O:0.42%、NaCl:0.05%、MgSO4・7H2O:0.3%、ビタミン溶液:1ml/L、pH:6.8)3Lが満たされた5L発酵器に、バチルス・サブチルス清麹醤(Bacillus subtilis var.chungkookjang,KCTC0697BP)菌株の培養液を1%接種し、攪拌速度150rpm、空気注入速度1vvmにて、37℃で72時間培養した後、2N硫酸溶液を加えてpHが3.0になるように調節し、ポリ−γ−グルタミン酸の含まれた試料液を得た。
本実施例では、本発明のポリ−γ−グルタミン酸が可溶性抗原に対して特異的免疫増強効果を現わしているか否かを調査するために、抗体特異的な免疫反応中、特に抗体産生と連関のあるB細胞による体液性免疫反応(humoral immune response)に及ぼす影響を調べた。抗原としては、豚の伝染性消火器疾患を誘発する豚伝染性胃腸炎ウイルス(Transmissible Gastroenteritis virus,TGE)の核タンパク質(N)を使用し、実験動物としてはウサギを使用した。
本実施例では、ポリ−γ−グルタミン酸が他の可溶性抗原に対し、腹腔投与方法によって特異的免疫(体液性免疫反応;humoral immune response)増強効果を現わしているか否かを酵母来由B型肝炎ウイルス(Hepatitis B virus,HBV)の表面抗原(surface antigen;L particle)を用いてBalb/c miceを実験動物として用いて確認した。
本実施例では、可溶性抗原の他に抗原性タンパク質を発現する微生物をワクチンの用途として用いる場合、本発明のポリ−γ−グルタミン酸が免疫補強剤として用いられて各抗原に対する特異的免疫{体液性免疫反応(humeral immune response)および粘膜免疫反応(mucosal immune response)}増強効果を現わすか否かを確認した。
本実施例では、豚の伝染性消火器疾患を誘発する豚伝染性胃腸炎ウイルス(Transmissible Gastroenteritis virus,TGE)の核タンパク質(N)抗原を表面発現する乳酸菌をポリ−γ−グルタミン酸と共に豚に経口投与するとき、免疫補強剤としての効果があるか否かを調べた。
Claims (8)
- 10〜10,000kDaの独立的に存在するポリ−γ−グルタミン酸と薬学的に許容される担体を含む抗体産生促進用組成物。
- 請求項1の抗体産生促進用組成物および;豚伝染性胃腸炎ウイルスの核タンパク質(N)、犬パルボウイルス抗原タンパク質VP2、またはB型肝炎ウイルスの表面抗原(L particle)である抗原性物質をを混合して得られるワクチン用組成物。
- 請求項2において、前記核タンパク質(N)抗原性物質は、核タンパク質(N)を発現する乳酸菌であり、前記VP2抗原性物質はVP2を発現する乳酸菌であることを特徴とするワクチン用組成物。
- 請求項2において、安定剤、乳化剤、水酸化アルミニウム、リン酸アルミニウム、pH調整剤、界面活性剤、リポソーム、免疫刺激複合体(ISCOM)補助剤、合成グリコペプチド、増量剤、カルボキシポリメチレン、細菌細胞壁、細菌細胞壁の誘導体、細菌ワクチン、動物ポックスウイルスタンパク質、ウイルス性物質(subviral)、粒子補助剤、コレラ毒素、N,N−ジオクタデシル−N’,N’−ビス(2−ヒドロキシエチル)−プロパンジアミン、モノホスホリル脂質A、ジメチルジオクタデシル−アンモニウムブロマイドおよびこれらの混合物から構成された群より選択されたいずれか一つ以上の第2補助剤を更に含むことを特徴とするワクチン用組成物。
- 請求項2において、前立腺癌、結腸癌、肺癌、乳癌、卵巣癌、頭頚部癌、外陰部癌、膀胱癌、脳癌および神経膠腫で構成された群より選択されたいずれか一つ以上の疾患の予防用または治療用であることを特徴とするワクチン用組成物。
- 請求項2のワクチン用組成物を、人間を除いた動物に注入し、抗原に対する抗体産生率を高める方法。
- 請求項6において、前記動物は哺乳類または鳥類であることを特徴とする方法。
- 請求項6において、注入は皮下注射、筋肉内注射、皮下内注射、腹膜内注射、鼻腔投与、口腔投与、経皮投与および経口投与から構成された群より選択されたいずれか一つの方法で行われることを特徴とする方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR2005-015955 | 2005-02-25 | ||
KR1020050015955A KR100517114B1 (ko) | 2005-02-25 | 2005-02-25 | 폴리감마글루탐산을 함유하는 면역보강제 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006232799A JP2006232799A (ja) | 2006-09-07 |
JP4769481B2 true JP4769481B2 (ja) | 2011-09-07 |
Family
ID=36927581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005128003A Active JP4769481B2 (ja) | 2005-02-25 | 2005-04-26 | ポリ−γ−グルタミン酸含有免疫補強剤組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080152615A1 (ja) |
EP (1) | EP1850870A4 (ja) |
JP (1) | JP4769481B2 (ja) |
KR (1) | KR100517114B1 (ja) |
CN (1) | CN101163500B (ja) |
AU (2) | AU2005328028A1 (ja) |
RU (1) | RU2390352C2 (ja) |
WO (1) | WO2006090968A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7785612B2 (en) * | 2005-04-20 | 2010-08-31 | Taiho Pharmaceutical Co., Ltd. | Polyamino acid for use as adjuvant |
US20080206276A1 (en) | 2005-07-08 | 2008-08-28 | Michael Otto | Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections |
JPWO2007024026A1 (ja) * | 2005-08-25 | 2009-03-05 | 明石 満 | T細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子 |
KR100582120B1 (ko) | 2005-10-20 | 2006-05-22 | 주식회사 바이오리더스 | 폴리감마글루탐산을 유효성분으로 함유하는 히알루로니다제저해제 |
KR100656560B1 (ko) * | 2005-12-29 | 2006-12-11 | 주식회사 바이오리더스 | 폴리감마글루탐산을 함유하는 항응고제 및 혈전예방용조성물 |
JP5166533B2 (ja) * | 2007-09-13 | 2013-03-21 | バイオリーダーズ コーポレーション | ポリガンマグルタミン酸を含むウイルス感染を予防する組成物 |
WO2009035174A1 (en) * | 2007-09-13 | 2009-03-19 | Bioleaders Corporation | Composition for treating or preventing atopic dermatitis comprising poly-gamma-glutamic acid |
KR20090037688A (ko) * | 2007-10-12 | 2009-04-16 | 주식회사 바이오리더스 | 폴리감마글루탐산을 함유하는 tlr 매개 세포성 면역증진용 조성물 |
WO2009088119A1 (en) * | 2008-01-07 | 2009-07-16 | Bioleaders Corporation | Composition for preventing or treating dry eye syndrome comprising poly-gamma-glutamic acid |
WO2009088118A1 (en) * | 2008-01-07 | 2009-07-16 | Bioleaders Corporation | Pharmaceutical composition for treating corneal wound comprising poly-gamma-glutamic acid |
JP5554407B2 (ja) * | 2009-06-25 | 2014-07-23 | バイオリーダーズ コーポレーション | ポリγ−グルタミン酸−キトサンナノ粒子を含有するアジュバント組成物 |
JP2011178764A (ja) * | 2010-03-04 | 2011-09-15 | Ajinomoto Co Inc | 腸内ビフィズス菌増殖促進剤および腸管バリア機能改善剤 |
KR101200960B1 (ko) * | 2010-11-10 | 2012-12-18 | 주식회사 바이오리더스 | 의료용 접착제 조성물 |
KR101297815B1 (ko) | 2010-11-18 | 2013-09-03 | 충남대학교산학협력단 | 폴리감마글루탐산과 광학영상다이의 복합체를 함유하는 센티넬 림프노드 감지용 광학영상 프로브 |
KR101398214B1 (ko) | 2011-04-06 | 2014-05-23 | 주식회사 바이오리더스 | 음이온성 고분자와 양이온성 고분자 이온복합체 기반 고감도 자기공명영상 나노조영제 및 이의 제조방법 |
WO2013147439A1 (ko) * | 2012-03-28 | 2013-10-03 | 한국식품연구원 | 청국장 추출물을 유효성분으로 포함하는 전신면역 또는 장관면역 보강제 |
KR101586468B1 (ko) * | 2014-12-30 | 2016-01-18 | 성균관대학교산학협력단 | 아주번트 조성물, 이의 제조 방법, 및 이를 포함하는 백신 조성물 |
KR101595949B1 (ko) * | 2015-05-27 | 2016-02-19 | 성균관대학교산학협력단 | 아주번트 조성물 및 백신 조성물의 제조 방법 |
KR101765600B1 (ko) | 2016-04-18 | 2017-08-07 | 주식회사 바이오리더스 | 폴리감마글루탐산의자궁경부상피이형증 치료용도 |
KR101794635B1 (ko) * | 2016-11-30 | 2017-11-07 | 주식회사 락토메이슨 | 막 필터를 이용한 고농도 사균의 제조방법 및 이의 제조방법으로 제조된 사균 |
KR102200773B1 (ko) | 2018-09-19 | 2021-01-12 | 주식회사 바이오앱 | 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물 |
KR102588606B1 (ko) | 2023-02-13 | 2023-10-13 | 주식회사 제이투케이바이오 | 녹차꽃에서 분리된 사카로마이세스 세레비지애 j2k-23(kctc 13695bp) 및 누룩에서 분리된 바실러스 서브틸리스 j2k-51(kctc 14053bp)의 혼합배양을 통한 화장료 조성물의 제조 및 폴리감마글루탐산의 생산 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4888193A (en) * | 1987-03-24 | 1989-12-19 | Takeda Chemical Industries, Ltd. | Bakery products and noodles containing polyglutamic acid |
US5202430A (en) * | 1990-01-16 | 1993-04-13 | University Of Tennessee | Transmissible gastroenteritis virus genes |
US5447732A (en) * | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
JP3669390B2 (ja) * | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
JPH10130166A (ja) * | 1996-08-20 | 1998-05-19 | Freunt Ind Co Ltd | 免疫原含有微小球体、その製造方法及びそれを用いた動物の免疫方法 |
JP3712530B2 (ja) * | 1998-05-28 | 2005-11-02 | キッコーマン株式会社 | 新種クリプトコッカス・ノダエンシス、それを用いる耐塩性耐熱性グルタミナーゼの製造法並びにグルタミン酸含量の多い蛋白加水分解物の製造法 |
KR20010078440A (ko) * | 2001-01-11 | 2001-08-21 | 김형순,성문희 | 고분자량의 폴리-감마-글루탐산을 생산하는 내염성 균주바실러스 서브틸리스 청국장 |
US20030129161A1 (en) * | 2001-09-17 | 2003-07-10 | Hsien-Jue Chu | Interleukin-12 as a veterinary vaccine adjuvant |
US20040057958A1 (en) * | 2002-05-17 | 2004-03-25 | Waggoner David W. | Immunogenicity-enhancing carriers and compositions thereof and methods of using the same |
KR100399091B1 (en) * | 2002-07-10 | 2003-09-22 | Bioleaders Corp | Macromolecular weight poly(gamma-glutamic acid) and its use |
AU2003271215A1 (en) * | 2002-10-17 | 2004-05-04 | Bioleaders Corporation | Vector for anti-hpv vaccine and transformed microorganism by the vector |
WO2005007804A2 (en) * | 2003-04-10 | 2005-01-27 | President And Fellows Of Harvard College | Anthrax conjugate vaccine and antibodies |
EP1629104A4 (en) * | 2003-06-04 | 2006-11-02 | Bioleaders Corp | CELL SURFACE EXPRESSION VECTOR OF SARS VIRUS ANTIGEN AND MICROORGANISMS THUS PROCESSED |
AU2004252091B2 (en) * | 2003-06-05 | 2010-06-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
GB0313916D0 (en) * | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
JP4860109B2 (ja) * | 2003-12-26 | 2012-01-25 | バイオリーダース・コーポレイション | ポリガンマグルタミン酸を含む免疫増強用組成物 |
KR20050079162A (ko) * | 2004-02-04 | 2005-08-09 | 주식회사 바이오리더스 | 파보바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 |
KR100582120B1 (ko) * | 2005-10-20 | 2006-05-22 | 주식회사 바이오리더스 | 폴리감마글루탐산을 유효성분으로 함유하는 히알루로니다제저해제 |
-
2005
- 2005-02-25 KR KR1020050015955A patent/KR100517114B1/ko active IP Right Grant
- 2005-04-26 JP JP2005128003A patent/JP4769481B2/ja active Active
- 2005-12-06 AU AU2005328028A patent/AU2005328028A1/en not_active Abandoned
- 2005-12-06 CN CN2005800487346A patent/CN101163500B/zh active Active
- 2005-12-06 EP EP05819088A patent/EP1850870A4/en not_active Withdrawn
- 2005-12-06 WO PCT/KR2005/004160 patent/WO2006090968A1/en active Application Filing
- 2005-12-06 RU RU2007135340/15A patent/RU2390352C2/ru active
- 2005-12-06 US US11/817,021 patent/US20080152615A1/en not_active Abandoned
-
2010
- 2010-05-12 AU AU2010201905A patent/AU2010201905A1/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
RU2007135340A (ru) | 2009-03-27 |
RU2390352C2 (ru) | 2010-05-27 |
AU2010201905A1 (en) | 2010-06-03 |
US20080152615A1 (en) | 2008-06-26 |
CN101163500B (zh) | 2013-01-02 |
CN101163500A (zh) | 2008-04-16 |
JP2006232799A (ja) | 2006-09-07 |
AU2005328028A8 (en) | 2008-09-18 |
EP1850870A4 (en) | 2009-01-28 |
WO2006090968A1 (en) | 2006-08-31 |
KR100517114B1 (ko) | 2005-09-27 |
EP1850870A1 (en) | 2007-11-07 |
AU2005328028A1 (en) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4769481B2 (ja) | ポリ−γ−グルタミン酸含有免疫補強剤組成物 | |
Li-Li et al. | Expression of infectious pancreatic necrosis virus (IPNV) VP2–VP3 fusion protein in Lactobacillus casei and immunogenicity in rainbow trouts | |
Min et al. | Immunogenicity of Lactobacillus-expressing VP2 and VP3 of the infectious pancreatic necrosis virus (IPNV) in rainbow trout | |
JP5327873B2 (ja) | リコンビナントヘリコバクターピロリの経口ワクチン及びその調製方法 | |
RU2410427C2 (ru) | Вирус собачьего гриппа, композиции, содержащие этот вирус, и способы их применения | |
CN105039372A (zh) | 一种核苷酸疫苗 | |
CA2957472C (en) | Attenuated bovine coronavirus and related vaccines | |
Huang et al. | Construction and immunogenicity analysis of Lactobacillus plantarum expressing a porcine epidemic diarrhea virus S gene fused to a DC-targeting peptide | |
CN113454102A (zh) | 非洲猪瘟疫苗 | |
US20180111964A1 (en) | Fusion polypeptide for immuno-enhancement and method for enhancing stimulation of immune response using the same | |
Lin et al. | Avian reovirus sigma C enhances the mucosal and systemic immune responses elicited by antigen-conjugated lactic acid bacteria | |
Sha et al. | Recombinant Lactococcus Lactis expressing M1-HA2 fusion protein provides protective mucosal immunity against H9N2 avian influenza virus in chickens | |
BR112021000025A2 (pt) | Composições e métodos para tratamento de doenças inflamatórias intestinais | |
US9119803B2 (en) | Carious tooth vaccine and preparation method | |
JP2010514412A (ja) | Dna魚ワクチン | |
JP2022527206A (ja) | 侵入プラスミド抗原bの最適化された無細胞合成、および関連する組成物、および使用方法 | |
KR100836893B1 (ko) | 콜로이드 금의 아쥬반트로의 사용 | |
JP2005082581A (ja) | 分泌型IgA抗体誘導剤 | |
JP4551001B2 (ja) | 脂肪酸を構成成分とするワクチン製剤 | |
KR102542601B1 (ko) | 신규한 돼지 유행성 설사병 바이러스 및 이의 용도 | |
US10098940B2 (en) | Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis | |
CN117202926A (zh) | 新型免疫调节平台及其使用方法 | |
SAN | Feasibility of probiotic lactobacillus and yeast as oral vaccine carrier against coronaviruses | |
TW201526910A (zh) | 豬胸膜肺炎放線桿菌ApxIIA蛋白於流感似病毒顆粒次單位疫苗製備之應用 | |
WO2012040806A2 (pt) | Composições imunogênicas sinérgicas baseadas em antígenos proteicos combinados com antígeno celular pertussis e toxinas inativadas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080812 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081111 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081209 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081225 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090112 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090331 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100622 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100916 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100922 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101021 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110614 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110620 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4769481 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140624 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |